Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Bearish flow noted in Gilead (GILD) with 1,949 puts trading, or 1.3x expected. Most active are 4/4 weekly 107 puts and Apr-25 109 puts, with ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00.

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, ...

The Handmaid's Tale season 6 showrunner Yahlin Chang promises a "full-scale rebellion" that will change everything for both ...

Live Updates Live Coverage Updates appear automatically as they are published. No Where to Hide 10:13 am The markets are ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral ...

The S&P 500 has officially entered correction territory, which means it is now more than 10% below its recent high of ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.